Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 11/20 | 0.37 |
| ▸ | GBA1 | P04062 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 9/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20726306 | 1.00 | SPHK1 (0.37) | SPHK1GBA1GAAGBA2SPHK2 | |
| SCHEMBL10511567 | 0.86 | ALDH1A1 (0.33) | GBA1ALDH1A1 | |
| SCHEMBL23912945 | 0.85 | GBA1 (0.50) | SPHK1GBA1GAAGBA2SPHK2 | |
| SCHEMBL20726262 | 0.85 | GBA1 (0.50) | SPHK1GBA1GAAGBA2SPHK2 | |
| SCHEMBL23517199 | 0.82 | GBA2 (0.53) | SPHK1GBA1GAAGBA2SPHK2 | |
| SCHEMBL19512642 | 0.82 | GBA2 (0.53) | SPHK1GBA1GAAGBA2SPHK2 | |
| SCHEMBL28793776 | 0.81 | SPHK1 (0.34) | SPHK1GBA1GBA2SPHK2 | |
| SCHEMBL16941609 | 0.81 | — | — | |
| SCHEMBL22208100 | 0.81 | — | — | |
| SCHEMBL16978990 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782655-A1 | A METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN AND DERIVATIVES | Amicus Therapeutics, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3441090-A1 | A METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN AND DERIVATIVES | Amicus Therapeutics, Inc. (US) | 2019-02-13 | — | — | EP | disclosed |